Oesophageal cancer in 2014: Advances in curatively intended treatment

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 2, 2015, Pages 74-75

  Lagergren, Jesper ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; PACLITAXEL;

CANCER GRADING; CANCER REGISTRY; CHEMORADIOTHERAPY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; DISEASE FREE SURVIVAL; ENDOSCOPIC MUCOSAL RESECTION; ESOPHAGUS CANCER; ESOPHAGUS DYSPLASIA; GASTROESOPHAGEAL REFLUX; HUMAN; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 84926079432     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.213     Document Type: Review

References (10)

1. Lagergren, J. & Lagergren, P. Oesophageal cancer. BMJ 341, c6280 (2010).
2. Tomizawa, Y. et al. Safety of endoscopic mucosal resection for Barrett's esophagus. Am. J. Gastroenterol. 108, 1440-1447 (2013).
3. Shaheen, N. J. et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N. Engl. J. Med. 360, 2277-2288 (2009).
4. Sjoquist, K. M. et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta?analysis. Lancet Oncol. 12, 681-692 (2011).
5. van Hagen, P. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366, 2074-2084 (2012).
6. Phoa, K. N. et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low?grade dysplasia: a randomized clinical trial. JAMA 311, 1209-1217 (2014).
7. Merkow, R. P. et al. Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. J. Natl Cancer Inst. 106, dju133 (2014).
8. Mariette, C. et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J. Clin. Oncol. 32, 2416-2422 (2014).
9. van Meerten, E. et al. Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: the Rotterdam experience. J. Surg. Oncol. 100, 32-37 (2009).
10. Oppedijk, V. et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J. Clin. Oncol. 32, 385-391 (2014).